CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
study drug, Nivolumab as a possible treatment for triple-negative breast cancer that has spread to other parts of the body.The inte...
Phase 2
Stamford, Connecticut, United States and 9 other locations
This research study involves pre-operative therapy that is specifically targeted for breast cancer in individuals with BRCA and PAL...
Phase 2
New Haven, Connecticut, United States and 8 other locations
participants with early-stage high-risk hormone receptor positive breast cancer.The names of the study drugs involved in this study...
Phase 2
Stamford, Connecticut, United States and 11 other locations
This research study is evaluating how well Breast Cancer responds to preoperative treatment with Endocrine treatment in combination ...
Phase 2
Stamford, Connecticut, United States and 10 other locations
This research study is for patients with metastatic breast cancer.* Metastatic means that the cancer has spread beyond the ...
Phase 2
Commack, New York, United States and 19 other locations
This is a randomized trial for patients with metastatic hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative breast...
Phase 2
Stony Brook, New York, United States and 12 other locations
therapy as a treatment after surgery for hormone receptor positive breast cancer.The study drugs involved in this study are:* A com...
Phase 2
Stamford, Connecticut, United States and 27 other locations
Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies avail...
Phase 3
Port Jefferson Station, New York, United States and 12 other locations
of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, stage II-III, Estrogen Receptor positive, HER-2 negative breast...
Phase 2
New Haven, Connecticut, United States and 14 other locations
DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with o ...
Phase 1, Phase 2
Commack, New York, United States and 71 other locations
Clinical trials
Research sites
Resources
Legal